Biochemical Engineering Special Interest Group
biological engineering professionals
20 December 2016

Bristol signs early-stage cancer virus deal with PsiOxus

Bristol-Myers Squibb has signed a new preclinical deal with British biotech PsiOxus to work on its oncolytic virus NG-348 in a deal that could be worth just shy of $1 billion. Oxford, U.K.-based PsiOxus gets $50 million upfront and could get as much as around $900 million in biobucks if it hits its marks in testing and beyond. Source: Fierce Biotech 20/12/2017

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).